Real-time Estimate
Cboe Europe
10:44:39 2024-06-10 am EDT
|
5-day change
|
1st Jan Change
|
1,620
GBX
|
-0.52%
|
|
+1.25%
|
+11.57%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
88,051
|
66,801
|
80,458
|
58,381
|
59,112
|
66,432
|
-
|
-
|
Enterprise Value (EV)
1 |
113,773
|
87,581
|
100,296
|
75,578
|
74,152
|
78,660
|
75,186
|
71,142
|
P/E ratio
|
19.2
x
|
11.8
x
|
18.6
x
|
3.93
x
|
11.9
x
|
11.8
x
|
10.2
x
|
9.2
x
|
Yield
|
4.5%
|
5.96%
|
4.98%
|
4.26%
|
4%
|
3.73%
|
3.87%
|
4.05%
|
Capitalization / Revenue
|
2.61
x
|
1.96
x
|
2.36
x
|
1.99
x
|
1.95
x
|
2.1
x
|
1.98
x
|
1.87
x
|
EV / Revenue
|
3.37
x
|
2.57
x
|
2.94
x
|
2.58
x
|
2.45
x
|
2.48
x
|
2.24
x
|
2
x
|
EV / EBITDA
|
9.51
x
|
9.19
x
|
8.85
x
|
7.23
x
|
6.37
x
|
7.4
x
|
6.42
x
|
5.61
x
|
EV / FCF
|
22.4
x
|
16.2
x
|
22.6
x
|
12.1
x
|
13.6
x
|
13.4
x
|
10.5
x
|
9.37
x
|
FCF Yield
|
4.46%
|
6.17%
|
4.42%
|
8.28%
|
7.36%
|
7.49%
|
9.52%
|
10.7%
|
Price to Book
|
7.35
x
|
4.58
x
|
5.34
x
|
5.47
x
|
4.4
x
|
4.14
x
|
3.4
x
|
2.81
x
|
Nbr of stocks (in thousands)
|
3,959,572
|
3,982,185
|
4,006,383
|
4,060,999
|
4,076,145
|
4,078,064
|
-
|
-
|
Reference price
2 |
22.24
|
16.78
|
20.08
|
14.38
|
14.50
|
16.29
|
16.29
|
16.29
|
Announcement Date
|
2/5/20
|
2/3/21
|
2/9/22
|
2/1/23
|
1/31/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
33,754
|
34,099
|
34,114
|
29,324
|
30,328
|
31,665
|
33,630
|
35,558
|
EBITDA
1 |
11,968
|
9,530
|
11,330
|
10,449
|
11,635
|
10,629
|
11,705
|
12,685
|
EBIT
1 |
8,972
|
8,906
|
8,806
|
8,151
|
8,786
|
9,202
|
10,186
|
11,242
|
Operating Margin
|
26.58%
|
26.12%
|
25.81%
|
27.8%
|
28.97%
|
29.06%
|
30.29%
|
31.62%
|
Earnings before Tax (EBT)
1 |
6,221
|
6,968
|
5,442
|
5,628
|
6,064
|
7,386
|
8,738
|
9,632
|
Net income
1 |
4,645
|
5,749
|
4,385
|
14,956
|
4,928
|
5,571
|
6,516
|
7,213
|
Net margin
|
13.76%
|
16.86%
|
12.85%
|
51%
|
16.25%
|
17.59%
|
19.38%
|
20.29%
|
EPS
2 |
1.158
|
1.426
|
1.082
|
3.662
|
1.216
|
1.377
|
1.597
|
1.771
|
Free Cash Flow
1 |
5,073
|
5,406
|
4,437
|
6,260
|
5,454
|
5,889
|
7,158
|
7,594
|
FCF margin
|
15.03%
|
15.85%
|
13.01%
|
21.35%
|
17.98%
|
18.6%
|
21.28%
|
21.36%
|
FCF Conversion (EBITDA)
|
42.39%
|
56.73%
|
39.16%
|
59.91%
|
46.88%
|
55.41%
|
61.16%
|
59.87%
|
FCF Conversion (Net income)
|
109.21%
|
94.03%
|
101.19%
|
41.86%
|
110.67%
|
105.71%
|
109.85%
|
105.27%
|
Dividend per Share
2 |
1.000
|
1.000
|
1.000
|
0.6125
|
0.5800
|
0.6069
|
0.6302
|
0.6600
|
Announcement Date
|
2/5/20
|
2/3/21
|
2/9/22
|
2/1/23
|
1/31/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
9,527
|
9,780
|
6,929
|
7,829
|
7,376
|
6,951
|
7,178
|
8,147
|
8,052
|
7,363
|
7,533
|
8,534
|
8,219
|
7,590
|
7,865
|
EBITDA
1 |
2,406
|
3,317
|
2,639
|
3,561
|
1,602
|
2,732
|
2,622
|
3,351
|
2,930
|
2,992
|
2,594
|
3,095
|
1,835
|
-
|
-
|
EBIT
1 |
1,893
|
2,613
|
2,008
|
2,605
|
1,595
|
2,092
|
2,170
|
2,772
|
1,752
|
2,443
|
2,216
|
2,793
|
1,757
|
2,408
|
2,487
|
Operating Margin
|
19.87%
|
26.72%
|
28.98%
|
33.27%
|
21.62%
|
30.1%
|
30.23%
|
34.02%
|
21.76%
|
33.18%
|
29.42%
|
32.72%
|
21.37%
|
31.73%
|
31.62%
|
Earnings before Tax (EBT)
1 |
706
|
2,598
|
896
|
1,012
|
1,626
|
1,907
|
1,987
|
1,791
|
379
|
1,355
|
1,823
|
2,493
|
1,317
|
-
|
-
|
Net income
1 |
749
|
1,802
|
975
|
10,315
|
1,495
|
1,490
|
1,624
|
1,464
|
350
|
1,046
|
1,425
|
1,877
|
1,214
|
-
|
-
|
Net margin
|
7.86%
|
18.43%
|
14.07%
|
131.75%
|
20.27%
|
21.44%
|
22.62%
|
17.97%
|
4.35%
|
14.21%
|
18.92%
|
21.99%
|
14.77%
|
-
|
-
|
EPS
2 |
0.1838
|
0.4488
|
0.2080
|
2.523
|
0.3650
|
0.3650
|
0.4010
|
0.3610
|
0.0860
|
0.2540
|
0.3505
|
0.4565
|
0.2280
|
-
|
-
|
Dividend per Share
2 |
0.2875
|
0.1750
|
0.1625
|
0.1375
|
0.1375
|
0.1400
|
0.1400
|
0.1400
|
0.1600
|
0.1500
|
0.1500
|
0.1500
|
0.1500
|
0.1594
|
0.1594
|
Announcement Date
|
2/9/22
|
4/27/22
|
7/27/22
|
11/2/22
|
2/1/23
|
4/26/23
|
7/26/23
|
11/1/23
|
1/31/24
|
5/1/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
25,722
|
20,780
|
19,838
|
17,197
|
15,040
|
12,228
|
8,754
|
4,710
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.149
x
|
2.18
x
|
1.751
x
|
1.646
x
|
1.293
x
|
1.15
x
|
0.7479
x
|
0.3713
x
|
Free Cash Flow
1 |
5,073
|
5,406
|
4,437
|
6,260
|
5,454
|
5,889
|
7,158
|
7,594
|
ROE (net income / shareholders' equity)
|
75%
|
44.4%
|
38.2%
|
43.9%
|
52.5%
|
42.8%
|
39.3%
|
35.9%
|
ROA (Net income/ Total Assets)
|
8.9%
|
7.18%
|
5.5%
|
8.08%
|
10.5%
|
9.68%
|
10.7%
|
11.2%
|
Assets
1 |
52,185
|
80,062
|
79,768
|
185,120
|
46,727
|
57,560
|
60,925
|
64,369
|
Book Value Per Share
2 |
3.020
|
3.660
|
3.760
|
2.630
|
3.290
|
3.930
|
4.800
|
5.790
|
Cash Flow per Share
2 |
2.000
|
2.090
|
1.960
|
1.810
|
1.670
|
1.760
|
1.840
|
1.960
|
Capex
1 |
1,265
|
1,226
|
1,172
|
1,143
|
1,314
|
1,774
|
1,659
|
1,650
|
Capex / Sales
|
3.75%
|
3.6%
|
3.44%
|
3.9%
|
4.33%
|
5.6%
|
4.93%
|
4.64%
|
Announcement Date
|
2/5/20
|
2/3/21
|
2/9/22
|
2/1/23
|
1/31/24
|
-
|
-
|
-
|
Last Close Price
16.29
GBP Average target price
20.36
GBP Spread / Average Target +25.01% Consensus |
1st Jan change
|
Capi.
|
---|
| +11.57% | 84.52B | | +46.85% | 765B | | -6.48% | 354B | | +20.07% | 331B | | +9.07% | 299B | | +18.87% | 248B | | -1.76% | 219B | | +10.91% | 216B | | +5.01% | 164B | | -3.00% | 162B |
Other Pharmaceuticals
|